Erimos Pharmaceuticals LLC is a biopharmaceutical company dedicated to the discovery and development of small molecule therapeutics aimed at treating cancer and viral diseases. Their lead product, Terameprocol, is designed to inhibit the expression of survivin and other SP1-regulated proteins that are often over-expressed in various cancers. This compound has been evaluated in multiple Phase I clinical trials, demonstrating long-term tolerability, disease stability, and anti-tumor activities across different cancer types, including solid tumors, leukemia, and high-grade glioma. Additionally, pre-clinical studies have indicated promising anti-viral effects, suggesting its potential utility beyond oncology.

The technology platform at Erimos focuses on targeting Sp1-regulated genes and proteins that are crucial for tumor cell replication and viral replication. Terameprocol, a semi-synthetic derivative of nordihydroguaiaretic acid (NDGA), is specifically engineered to promote selective tumor cell death while minimizing toxicity to healthy cells. The company has developed a novel extraction process for NDGA from the Larrea tridentata plant, enhancing the pharmacological profile of Terameprocol. Ongoing clinical studies are exploring various administration routes, including intravenous, intravaginal, and oral formulations, with the aim of improving patient outcomes and expanding the therapeutic applications of their lead compound.

United States

Erimos is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics to treat cancer and viral diseases. We are dedicated to harnessing our innovative technology to meaningfully improve the lives and health outcomes of patients.

Erimos Pharmaceuticals LLC

Company Details